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Despite the exponential growth in research following the
rapid spread of SARS-CoV-2 and subsequent COVID-19
pandemic, the underlying pathophysiological mechanisms
in COVID-19 patients remain poorly understood. The in-
creased incidence of cardiovascular and thromboembolic
complications, immune cell deactivation and sepsis-like
multiple organ failure suggests the involvement of mul-
tiple pathways. Accordingly, recent studies have proposed
that virus-induced endothelial dysfunction and damage,
resulting in impaired vascular blood flow, coagulation and
leakage, may partially explain the development of organ
dysfunction and oedema [1]. Hence, the development of
endotheliitis may be a prominent, yet partly under recog-
nised, feature of COVID-19 induced critical illness.
Whilst numerous pro-inflammatory cytokines and blood
biomarkers have already been compared in patients with
different severities of COVID-19 - to date - no study, re-
port or editorial has described the potential role of adre-
nomedullin (ADM) during the host response to COVID-
19. This is surprising, since ADM has been shown to play
a key role in reducing vascular (hyper) permeability and
promoting endothelial stability and integrity following se-
vere infection [2]. Thus, ADM may also be of interest
within COVID-19 induced endotheliitis. Indeed, a recent
study investigating gene upregulation in patients with sys-
temic capillary leak syndrome (SCLS), characterised by
plasma leakage into peripheral tissue and transient epi-
sodes of hypotensive shock and oedema, found that ADM
was not only one of the most upregulated genes, but that
subsequent application to endothelial cells resulted in a
protective effect on vascular barrier function [3].
Furthermore, recent clinical studies on sepsis patients
upon emergency department (ED) presentation and
during intensive care (ICU) treatment using the stable
protein surrogate, mid-regional proadrenomedullin
(MR-proADM), found that its assessment could accur-
ately identify disease progression in patients with non-
severe clinical signs and symptoms, safely increase out-
patient treatment with decreased readmission rates and
no subsequent mortalities [4], and identify patients re-
quiring a rapid administration of antibiotics or triage to
the ICU [5]. Despite the low number of severe viral cases
within each of these studies (between 2.1% [3] and 3.4%
[4]), similar hypotheses can also be formulated for pa-
tient populations with COVID-19.
The assessment of MR-proADM in future COVID-19
studies may therefore provide important information
into the pathophysiological mechanisms underlying
endotheliitis and subsequent organ dysfunction. The
early identification of patients likely to develop severe
clinical symptoms requiring subsequent hospitalisation,
as well as the safe discharge of those already hospita-
lised, may be of particular importance in regions where
healthcare systems are used to full capacity.
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